Objective: To observe the clinical effect of botulinum toxin type A (BTA) injection into the salivary glands of the severe neurological patients with tracheotomy. Methods: Seven patients with severe neurological disorders after tracheotomy and obvious drooling symptoms were enrolled. BTA was injected into bilateral parotid glands and submandibular glands under the guidance of ultrasound. Unstimulated salivary flow rate (uSFR) and Drooling Severity and Frequency Scale (DSFS) were used to evaluate drooling before injection, 1 week, and 4 weeks after injection. We compared the extubation time, time of changing from balloon cannula to metal cannula, hospitalization time and incidence of recurrent pulmonary infection between these patients and other patients accepted conventional curation. Results: (1) The drooling severity scale (DSFS-S), the drooling frequency scale (DSFS-F), the drooling frequency and severity scale total score (DSFS-T) were significantly lower at 4 weeks after BTA injection compared to prior-treatment (p
CITATION STYLE
Shao, M., Chen, K., Wu, X., Lin, J., Jiang, M., Zhuo, F., … Huang, Y. (2023). Botulinum toxin in the treatment of sialorrhea in severe neurological patients with tracheotomy. Brain and Behavior, 13(8). https://doi.org/10.1002/brb3.3164
Mendeley helps you to discover research relevant for your work.